May 29, 2020
Newsam has provided his expertise in scientific and strategic consulting to multiple US Fortune500 companies, as well as early-phase biotech and materials companies around the globe, including the US, UK, and Korea. He has worked with notable government institutions such as IFP Energies Nouvelles, and he has been a respected member of many academic advisory committees.
Newsam provides an overview of
Tioga Research, their objectives in research, and overall mission.
As he states, they are heavily involved in research and early
development of formulations applied to the
skin, including pharmaceutical (primary) as well as the
care area as well.
Newsam explains how ‘active’ ingredients are diffused into the skin in order to achieve the desired therapeutic benefit, and he talks about transdermal delivery of drugs, and why this method can be particularly useful.
The research CEO provides an
overview of active and inactive ingredients, and FDA-approved
products. As he states, cocktails of molecules tend to work best
for delivering the benefits to users. Newsam explains how they have
worked to assemble a long list of safe compounds and mixtures, and
databases of useful excipients (inactive substances).
Continuing, Newsam delivers an overview of what manufacturers can claim regarding their products and the benefits they may provide. As he states, in theory, any claim of benefit should be supported by a scientific study, but the cosmetic industry is so large, with so many products on the market, it can be difficult to police every product that exists.
Additionally, Newsam talks about
other drugs, permeability, and how enzymes can degrade proteins.
Newsam is a materials chemist by training, and he has authored in
excess of 170 scientific publications.
Visit these links to find out more about John M. Newsam: